Escherichia Coli

• Rx Only*

Adults and children: At the onset of symptoms, dissolve 5 pellets under the tongue 3 times a day until symptoms are relieved or as directed by a doctor.

1. 1Tachycardia22559%
2. 2Haemorrhagic Stroke22459%
3. 3Fall21657%
4. 4Ocular Discomfort21556%
5. 5Diarrhoea21456%
6. 6Altered State Of Consciousness21356%
7. 7Pruritus21356%
8. 8Haematemesis21256%
9. 9Amaurosis Fugax21155%
10. 10Blindness21155%
11. 11Chills21155%
12. 12Head Discomfort21155%
13. 13Arthralgia21055%
14. 14Cardio-respiratory Arrest21055%
15. 15Eye Pain21055%

Recent PubMed references pinned to Escherichia Coli as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Intranasal Delivery of Bacterial Extracellular Vesicles Enables RNA Cargo Entry Into the Brain.
  Journal of extracellular vesicles · 2026 · Ha JY, Kim SM, Choi SY, et al.
  PMID 42275483DOI 10.1002/jev2.70320
• The RecBCD complex interacts directly with the DNA sliding clamp in Escherichia coli.
  Nucleic acids research · 2026 · Riisnæs IMM, Ræder SB, Simonsen S, et al.
  PMID 42273914DOI 10.1093/nar/gkag570
• A census of anti-CRISPR proteins reveals AcrIE9 and AcrIE13 as inhibitors of the Escherichia coli K12 type IE CRISPR-Cas system.
  Proceedings of the National Academy of Sciences of the United States of America · 2026 · Taranenko D, Kotovskaya O, Kuznedelov K, et al.
  PMID 42258724DOI 10.1073/pnas.2529903123
• Empirical evaluation of all unique Cas9 protospacers in E. coli reveal widespread functionality and rules for gRNA design.
  Nucleic acids research · 2026 · Kammerdiener EK, Hren AP, Harrison R, et al.
  PMID 42258532DOI 10.1093/nar/gkag548
• Genomic Map of Escherichia coli and Single Nucleotide Polymorphism Markers in Colorectal Cancer.
  Microbial biotechnology · 2026 · Xi Y, Liping Z, Yating X, et al.
  PMID 42249581DOI 10.1111/1751-7915.70397
• Global prevalence of fluoroquinolone resistance in Escherichia coli causing urinary tract infections: a systematic review and meta-analysis.
  Frontiers in cellular and infection microbiology · 2026 · Zhou H, Xue T, Xue J, et al.
  PMID 42246010DOI 10.3389/fcimb.2026.1831616
• Multi-screening of beta-lactam antibiotics in milk based on Fe(3)O(4)@phage/bacteria system and aggregation induced emission luminogen.
  Analytica chimica acta · 2026 · Wang SH, Ma N, Wang JP, et al.
  PMID 42242819DOI 10.1016/j.aca.2026.345687
• Phenotypic and genotypic characterization of biofilm-forming Escherichia coli from subclinical bovine mastitis and association with antimicrobial resistance.
  BMC veterinary research · 2026 · Khalefa HS, Ali AM, Farag HS, et al.
  PMID 42237335DOI 10.1186/s12917-026-05598-2

The 10 most recently updated of 413 ClinicalTrials.gov registrations naming Escherichia Coli as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
  Recruiting · Phase 2 · Interventional · 461 enrolled · National Cancer Institute (NCI)
  NCT04546399updated 2026-06-12
• Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.
  Completed · Phase 2 · Interventional · 63 enrolled · Immuron Ltd.
  NCT05933525updated 2026-06-12
• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
  Recruiting · Phase 2 · Interventional · 153 enrolled · National Cancer Institute (NCI)
  NCT06317662updated 2026-06-11
• Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
  Not yet recruiting · Phase 2 · Interventional · 90 enrolled · SWOG Cancer Research Network
  NCT07636564updated 2026-06-09
• Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
  Recruiting · Phase 2 · Interventional · 80 enrolled · Children's Oncology Group
  NCT02981628updated 2026-06-05
• A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
  Completed · Phase 3 · Interventional · 17,935 enrolled · Janssen Research & Development, LLC
  NCT04899336updated 2026-06-05
• A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
  Recruiting · Phase 2 · Interventional · 222 enrolled · National Cancer Institute (NCI)
  NCT06124157updated 2026-06-03
• TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
  Active not recruiting · Phase 2 · Interventional · 69 enrolled · St. Jude Children's Research Hospital
  NCT03849651updated 2026-06-03
• Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
  Active not recruiting · Phase 3 · Interventional · 669 enrolled · National Cancer Institute (NCI)
  NCT02101853updated 2026-06-03
• Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
  Active not recruiting · Phase 3 · Interventional · 440 enrolled · Children's Oncology Group
  NCT05602194updated 2026-06-02

Frequently asked questions

What is Escherichia Coli used for?

According to FDA labeling, Escherichia Coli carries indications including: Rx Only*. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Escherichia Coli?

Escherichia Coli is classified as Antidiarrheal microorganisms.